Invivyd

Contributing Author

Recent Articles by Invivyd

May-27	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus IVVD GlobeNewswire
May-23	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas IVVD GlobeNewswire
May-21	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 IVVD GlobeNewswire
May-15	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights IVVD GlobeNewswire
May-14	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy IVVD GlobeNewswire
May-13	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference IVVD GlobeNewswire
May-12	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles IVVD GlobeNewswire
May-08	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 IVVD GlobeNewswire